Biomunex Pharmaceuticals Overview
- Founded
- 2014
- Status
- Private
- Latest Deal Type
- Seed
- Investors
- 3
Biomunex Pharmaceuticals General Information
Description
Developer of immunotherapies through a bispecific antibody intended to developing therapeutics in the area of immuno-oncology. The company's platform offers to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks, in a timely and cost-effective manner.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 14 avenue d'Eylau
- 75116 Paris
- France
Biomunex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Seed Round | Completed | Generating Revenue | ||||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Grant | 01-Jan-2016 | Completed | Startup | |||
| 1. Grant | 01-Jan-2014 | Completed | Startup |
Biomunex Pharmaceuticals Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Pierre-Emmanuel Gerard | Co-Founder & Chief Executive Officer | ||
| Eugene Zhukovsky Ph.D | Chief Scientific Officer | ||
| Jean-Pierre Mach | Co-Founder |
Biomunex Pharmaceuticals Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| L'Agence Nationale de la Recherche | Government | 000 0000 | 000000 0 | ||
| Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
| Agoranov | Accelerator/Incubator | 000 0000 | 000000 0 |